AFT new FDA approval could be a shot in the arm

AFT new FDA approval could be a shot in the arm
Analyst sentiment is positive after FDA approval of Maxigesic IV. (Image: Hyloris Pharmaceuticals)
Ben Moore
AFT Pharmaceuticals had a bump in share price on Wednesday morning following approval of its intravenous post-operative pain relief drug by the United States Food and Drug Administration.Following the announcement of the approval of Maxigesic IV, which came in overnight, the stock lifted 16 cents per share to $3.56 at the open on the New Zealand stock exchange (NZX), up from $3.40 at yesterday's close. It has since dipped to $3.50.AFT co-founder and managing director Hartley Atkinson said they were delighted to receive the second appro...

More Markets

The invidious position of Nvidia in the AI boom
Markets

Paul McBeth: The invidious position of Nvidia in the AI boom

Big Tech is writing blank cheques chasing the AI dragon, but NZ is more circumspect.

The Warehouse: Adamantem still hunting a bargain
Markets

The Warehouse: Adamantem still hunting a bargain

Sources told BusinessDesk Adamantem believed its offer was compelling.

The NZ dollar has a spring in its step
Economy

The NZ dollar has a spring in its step

The kiwi gained more than 5% against the greenback in August. 

ForBarr on fence about Fletcher pipe deal
Infrastructure

ForBarr on fence about Fletcher pipe deal

There are still 'key unknowns', the analysts said.